The difference between a prescription and a physician.
Semaglutide and tirzepatide are the most effective weight loss medications ever developed. But a prescription without a protocol is a missed opportunity. Dr. Seth Lampert manages every aspect of your GLP-1 therapy — labs, dosing, side effects, body composition.
Schedule your evaluationNo rotating providers, no nurse practitioner handoffs. Dr. Lampert is your physician from first evaluation through maintenance. He knows your history because he wrote it.
GLP-1 therapy affects more than weight. Dr. Lampert tracks metabolic markers, thyroid function, nutrient levels, and body composition. The goal is fat loss with muscle preserved.
The GLP-1 landscape is evolving fast — new medications, formulations, and combination therapies. Dr. Lampert stays current with every FDA approval and clinical trial so your protocol reflects what actually works best.
Dr. Lampert prescribes the full range of FDA-approved GLP-1 medications based on your metabolic profile, insurance situation, and clinical goals. As new agents receive approval, they become available to patients immediately.
The original GLP-1 breakthrough. 15–17% average body weight loss in clinical trials. Weekly injection with the most established safety profile in the class.
Dual GLP-1/GIP receptor agonist. Up to 22.5% average weight loss in clinical trials — the highest of any approved medication. Often the better choice for patients who need significant metabolic intervention.
Daily oral tablet for patients who prefer not to inject. Effective for weight management and metabolic improvement, though typically with more modest results than injectable formulations.
Next-generation oral semaglutide, amycretin, survodutide, and other agents are advancing through FDA review. Dr. Lampert tracks the pipeline and incorporates new options as they become available.
Wellesley Medical currently serves patients in Massachusetts and Rhode Island via telehealth.
Semaglutide (Ozempic, Wegovy) targets the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) targets both GLP-1 and GIP receptors. Clinical trials show tirzepatide produces greater average weight loss, but individual response varies significantly. Dr. Lampert evaluates your metabolic profile, medication history, and goals to determine which is right for you.
Yes. Dr. Lampert prescribes all FDA-approved GLP-1 and dual-receptor agonist medications, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and newer agents as they receive approval. The specific medication depends on your clinical profile and goals.
Most online clinics run a questionnaire, write a prescription, and disappear. At Wellesley Medical, Dr. Lampert is your physician from day one. He orders labs, monitors your metabolic markers, adjusts dosing based on your response, and manages side effects. You see the same doctor every time.
Absolutely. The GLP-1 landscape is evolving rapidly, with new medications, formulations, and combination therapies advancing through FDA review. Dr. Lampert actively follows the latest clinical research and regulatory approvals. As new options become available, your protocol can evolve to include the most effective treatments.
The initial evaluation is $600 one-time. Ongoing care is $350 per month. This covers all physician consultations, lab interpretation, medication management, and ongoing monitoring. Medications are purchased separately through your pharmacy or manufacturer savings programs.